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Excision of breast cancer often leads to dis-figurement and asymmetry of the breast that requires reconstruction. A recent addi-
tion to the field of breast reconstruction is fat 
grafting.1 Fat grafting was once banned by the 
American Society of Plastic Surgeons because of 
raised concerns about its interference with the 
detection of breast cancer.2 However, since the 
early 2000s, fat grafting has been rediscovered 
and reassessed.3,4 As supportive evidence for the 
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Background: The authors investigate the in vitro and in vivo interaction of hu-
man breast cancer cells and human adipose-derived stem cells to address the 
controversy on the safety of postmastectomy fat grafting.
Methods: The authors co-cultured human adipose-derived stem cells and MDA-
MB-231 breast cancer cells in an in vitro cell migration assay to examine the 
migration of breast cancer cells. In the in vivo arm, the authors injected breast 
cancer cells (group I), human breast cancer cells plus human adipose-derived 
stem cells (group II), human breast cancer cells plus human fat graft (group III), 
and human breast cancer cells plus human fat graft plus human adipose-derived 
stem cells (group IV) to the mammary fat pads of female nude mice (n = 20). 
The authors examined the tumors, livers, and lungs histologically after 2 weeks.
Results: Migration of breast cancer cells increased significantly when 
 co-cultured with adipose-derived stem cells (p < 0.05). The tumor 
growth rate in group IV was significantly higher than in groups I and 
II (p < 0.05). The tumor growth rate in group III was also higher than 
in groups I and II, but this difference was not statistically significant 
(p > 0.05). Histologically, there was no liver/lung metastasis at the end of 
2 weeks. The vascular density in the tumors from group IV was significantly 
higher than in other groups (p < 0.01).
Conclusion: The injection of breast cancer cells, fat graft, and adipose-derived 
stem cells together increases breast cancer xenograft growth rates significant-
ly. (Plast.  Reconstr. Surg. 142: 1489, 2018.)
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EXPERIMENTAL
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safety of fat grafting increased, the position of 
the American Society of Plastic Surgeons has 
also evolved. In 2009, the American Society of 
Plastic Surgeons Fat Graft Task Force lifted the 
ban on autologous fat grafting and released new 
recommendations on the safety and efficacy of 
postmastectomy fat grafting.5 The Task Force 
reported no interference with breast cancer sur-
veillance after fat grafting to the breast; however, 
it did not discuss whether fat grafting modifies 
the risk of breast cancer recurrence in postresec-
tion patients.5
Since that time, the incidence of fat grafting as 
an adjunct to breast reconstruction has increased 
significantly. Relatively low fat graft retention 
rates, estimated between 20 and 75 percent,6,7 
have discouraged surgeons from using fat grafting 
as a primary method of reconstruction, and can 
require patients to undergo multiple treatments 
to achieve the desired result. However, the modi-
fication of enriching fat grafts, or co-injecting a 
preexpanded adipose-derived stem cell popula-
tion, has shown great promise in increasing fat 
graft retention.8,9
Adipose-derived stem cells are known to 
secrete growth factors and cytokines that pro-
mote tissue regeneration and revascularization, 
processes important for fat survival but also crit-
ical to cancer growth and metastasis (Fig. 1).10–13 
This discovery brought in a major controversy 
on whether fat grafting will increase the risk of 
tumor recurrence in postmastectomy patients. 
The most striking aspect of this controversy is 
the opposing results obtained from basic scien-
tific and clinical studies. Several groups have 
repeatedly documented that adipose-derived 
stem cells increase the growth and migration of 
breast cancer cells under experimental condi-
tions.14,15 Interestingly, clinical studies failed to 
document any increase in breast cancer recur-
rence caused by postmastectomy fat grafting.16–18 
Cases of breast cancer recurrence that may be 
linked to fat grafting have been reported; how-
ever, these are sporadic and the number of 
patients too few for a definitive conclusion.19,20 
In this study, we address this controversy by 
examining the in vivo and in vitro interactions 
of human adipose-derived stem cells and breast 
cancer cells using a clinically relevant experi-
mental design.
MATERIALS AND METHODS
The human and animal experiments were 
approved by the Institutional Review Board 
(approval no. 254494-9) and Institutional Animal 
Care and use Committee (approval no. 18296).
In Vitro Migration Assay
In the in vitro arm of the study, we examined 
the interaction of breast cancer cells and human 
adipose-derived stem cells using a migration assay 
chamber (Cell Biolabs, Inc., San Diego, Calif.). 
We obtained adipose tissue from patients (n = 3) 
by means of liposuction and harvested human 
adipose-derived stem cells from these samples by 
means of enzymatic digestion using our previously 
published technique.14 The migration assay was 
performed as instructed by the manufacturer. In 
study groups, we seeded the lower chamber with 
human adipose-derived stem cells from passages 
III to V at a density of 1.0 × 106/ml. In control 
groups, the lower chamber was filled with either 
cell culture medium (Dulbecco’s Modified Eagle 
Medium, 10% fetal bovine serum, and 1% antibi-
otic/antimycotic solution or phosphate-buffered 
saline; all from GE Healthcare Bio-Sciences, Pitts-
burg, Pa.). All of the groups were set up in tripli-
cate. We quantified the number of migrated breast 
cancer cells in each group using a fluorescent plate 
reader (Molecular Devices, Sunnyvale, Calif.) and 
expressed the results in relative fluorescence units.
In Vivo Study
For the in vivo arm of the study, we harvested 
fat tissue from a single donor by means of lipo-
suction. We divided the fat tissue into two halves 
and isolated stromal vascular fraction cells from 
the first half by means of enzymatic digestion as 
described previously.14,21 The second half was pro-
cessed by means of the Coleman technique for 
fat graft.3 We labeled the stromal vascular frac-
tion cells with 3,3′-dioctadecyloxacarbocyanine, 
perchlorate (DiO) for in vivo tracking purposes. 
This mixture of stromal vascular fraction, MDA-
MB-231/red fluorescent protein–positive human 
breast cancer cells, and fat graft was then injected 
into the bilateral fourth mammary fat pads of 
female nude mice using 18-gauge needle tips 
(n = 20) as shown in Table 1. The number of cells 
in each group was 8 × 105 breast cancer cells and 
1.8 × 105 stromal vascular fraction to each mam-
mary fat pad. In this study, we used a lower num-
ber of breast cancer cells for the in vivo arm to 
obtain a more clinically relevant experimental 
model. We followed tumor growth with digital 
caliper measurements every other day and calcu-
lated the tumor volume using the formula (length 
× width2)/2. The animals were killed 2 weeks after 
Copyright © 2018 American Society of Plastic Surgeons. Unauthorized reproduction of this article is prohibited. 
Volume 142, Number 6 • Breast Cancer and Fat Grafting
1491
inoculation, and the tumors, lungs, and livers 
were removed for histologic examination.
Histology
The excised tumors and organs were embed-
ded in optimal cutting temperature compound 
(VWR International, Radnor, Pa.) and frozen in 
cold acetone (EMD Millipore, Billerica, Mass.). 
The frozen blocks were cut into 5-μm sections 
using a cryostat and stained using hematoxylin 
and eosin and immunofluorescence.
For hematoxylin and eosin staining of the 
breast cancer tumors, we randomly selected one 
tumor from every animal in each group (n = 5) and 
obtained five sections from each tumor. We used 
these sections to evaluate the general composition 
of the tumors and also to measure the percentage 
volume of fat tissue in each tumor using ImageJ 
software (National Institutes of Health, Bethesda, 
Md.).22 We subtracted the percentage volume of fat 
tissue in each group from the total volume of breast 
cancer tumors that we obtained with digital caliper 
Fig. 1. Main pathways of interaction between adipose tissue and breast cancer cells. ASCs, adipose-derived stem cells; VEGF, vas-
cular endothelial growth factor; IL-6, interleukin-6; TNF-α, tumor necrosis factor-alpha; IGF-1, insulin like growth factor-1; LEPR-
B, leptin receptor-B; AdipoR1/R2, adiponectin receptor 1/2; NFƘβ, nuclear factor kappa-light-chain-enhancer of activated B cells; 
ERK1/2, mitogen-activated protein kinase 3/1; ERα, estrogen receptor alpha; PI3K, phosphatidylinositol-4,5-bisphosphate 3-kinase; 
Akt, protein kinase B; mTOR, mechanistic target of rapamycin; JAK2/STAT3, Janus kinase 2/signal transducer and activator of tran-
scription 3. (Adapted from Park J, Euhus DM, Scherer PE. Paracrine and endocrine effects of adipose tissue on cancer development 
and progression. Endocr Rev. 2011;32:550–570; and van Kruijsdijk RC, van der Wall E, Visseren FL. Obesity and cancer: The role of 
dysfunctional adipose tissue. Cancer Epidemiol Biomarkers Prev. 2009;18:2569–2578.)
Table 1. Study Groups
Group
 
Injection Volume 
(μl)
Injected  
Mixture
Cell  
Suspension
Fat  
Graft
I BrCa only 150 —
II BrCa + hASCs 150 —
III BrCa + fat graft 75 75
IV BrCa + hASCs + fat graft 75 75
BrCa, breast cancer cells; hASCs, human adipose-derived stem cells.
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measurements. The rationale for doing this was to 
eliminate the contribution of remaining fat graft vol-
ume to the total tumor volume in groups III and IV 
(i.e., a false increase in breast cancer tumor volume) 
so that we could make a comparison of only breast 
cancer tumor volumes. For hematoxylin and eosin 
staining of livers and lungs, we randomly selected 
three animals from each group and obtained 12 sec-
tions from the livers and lungs of these animals. We 
used these sections to detect organ micrometastasis 
from the primary breast cancer tumor.
We examined the sections from groups II and 
IV under fluorescence microscopy before immu-
nofluorescence staining to detect any DiO-positive 
stromal vascular fraction cells. Afterward, we per-
formed von Willebrand factor immunofluores-
cence staining to detect the average vessel density 
in tumors. In every animal, we randomly selected 
either the right or the left breast cancer xenograft 
and obtained 12 sections from that tumor, for a total 
of 60 sections per group. We incubated the tissue 
sections with a rabbit anti–von Willebrand factor 
primary antibody (Abcam, Inc., Cambridge, Mass.) 
overnight at 4°C. We used anti-rabbit fluorescence 
isothiocyanate (Abcam) as a secondary antibody. 
The nuclei were counterstained with 4′,6-diamid-
ino-2-phenylindole (Vector Laboratories, Burlin-
game, Calif.), and the images were captured under 
a fluorescence microscope (Zeiss AxioObserver.Z1; 
Carl Zeiss, Oberkochen, Germany). The number 
of vessels in each section was counted manually.
In addition to hematoxylin and eosin stain-
ing of livers and lungs, we performed anti–red 
fluorescent protein immunofluorescence staining 
to detect breast cancer micrometastasis in these 
organs. We randomly selected three animals from 
each group and obtained 12 sections from the liv-
ers and lungs of these animals. We incubated the 
tissue sections with a rabbit anti–red fluorescent 
protein antibody (Thermo Scientific, Rockford, 
Ill.). Counterstaining of the nuclei and imaging 
was performed as described above.
Statistical Analysis
All results were compared using the one-way 
analysis of variance test and, if necessary, the Tukey 
test. A value of p < 0.05 was considered significant.
RESULTS
In Vitro Migration Assay
Two of three human adipose-derived stem 
cell populations increased the migration of breast 
cancer cells significantly (p < 0.05) (Fig. 2). The 
third human adipose-derived stem cell line also 
increased the migration of breast cancer cells but 
not to a statistically significant degree (p > 0.05). 
The average fluorescence from the wells with only 
breast cancer cells was 6.5 × 106 ± 1.4 × 106 relative 
fluorescence units, whereas the average fluores-
cence from the wells with human adipose-derived 
stem cells and breast cancer co-cultures were 9.2 
× 106 ± 3.2 × 105 (p < 0.05), 9.3 × 106 ± 8.1 × 105  
(p < 0.05), and 7.4 × 106 ± 5.7 × 105 (p > 0.05) rela-
tive fluorescence units for human adipose-derived 
stem cell lines 1, 2, and 3, respectively. The fluo-
rescence from control wells containing only cul-
ture medium and phosphate-buffered saline were 
negligible (Fig. 2).
In Vivo Study
All of the animals survived surgery and even-
tually developed tumors at the injection sites. 
Before subtraction of the fat graft volume, the 
average breast cancer tumor volumes on day 15 
were 341.2 ± 155.1, 365.4 ± 148.2, 748.7 ± 378.6, 
and 1121.6 ± 667.3 mm3 in groups I, II, III, and 
IV, respectively. (See Figure, Supplemental Digital 
Content 1, which shows the graph with the tumor 
volumes measured initially and before subtracting 
the percentage volume of fat tissue in each tumor, 
http://links.lww.com/PRS/D97.) The tumor vol-
umes after adjustment were 327.2 ± 148.8, 344.2 ± 
151.9, 677.3 ± 145.1, and 1024.62 ± 481.6 mm3 in 
groups I, II, III, and IV, respectively (Fig. 3). The 
tumors in group IV (breast cancer cells plus adi-
pose-derived stem cells plus fat graft) were larger 
Fig. 2. Graph summarizing the results of in vitro migration assay. 
Human adipose-derived stem cell populations 1 and 2 signifi-
cantly increased the migration of breast cancer cells. *p < 0.05. 
BrCa, breast cancer cells; hASCs, human adipose-derived stem 
cells; CM, culture medium; PBS, phosphate-buffered saline.
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than the tumors in groups I (breast cancer cells 
only), II (breast cancer plus adipose-derived stem 
cells), and III (breast cancer cells plus fat graft) 
at almost all time points (p < 0.05) There was no 
difference between the tumor volumes in group 
III versus groups I and II (p > 0.05) except on day 
2 after injection (Fig. 3). The adjustment of the 
tumor volumes by subtracting the fat tissue vol-
ume did not change our statistical results.
Histology
Hematoxylin and eosin staining of the tumors 
revealed that almost all of the fat tissue injected 
in groups III and IV was replaced by breast can-
cer tissue (Fig. 4, left). The percentage fat volumes 
within the tumors in groups I, II, III, and IV were 
4.1 ± 2.7, 5.8 ± 3.5, 11.4 ± 6.7, and 11.9 ± 6.4 per-
cent, respectively. There was no significant differ-
ence across the groups (p < 0.05) (Fig. 4, right). 
Because the adjustment of the tumor volumes by 
subtracting the percentage fat volume from the 
total tumor volume did not alter our statistical 
results, we concluded that the injected fat tissue in 
groups III and IV did not contribute significantly 
to the final tumor volume.
The vascular density (vessels per high-power 
field) in the tumors from group IV (20.3 ± 3.1) 
was significantly higher in comparison with 
tumors from groups I (12.3 ± 1.7), II (12.7 ± 2.3), 
and III (18.8 ± 3.7) (p < 0.01) (Fig. 5). We failed to 
observe any DiO-positive stromal vascular fraction 
cells remaining within the tumors after 2 weeks 
(Fig. 6). This suggests that the injected stromal 
vascular fraction cells did not survive in vivo.
Hematoxylin and eosin staining of livers and 
lungs did not reveal any micrometastasis in these 
organs (Fig. 7). These results were confirmed with 
red fluorescent protein immunofluorescence 
staining. We could not detect any red fluorescent 
protein–positive breast cancer cells in the livers 
and lungs of the animals (Fig. 8).
Summary of Findings
In our in vitro migration assay, we found that 
adipose-derived stem cells increased the migra-
tion of breast cancer cells. The in vivo arm of this 
study demonstrated that co-injection of adipose-
derived stem cells and breast cancer cells and of fat 
graft with breast cancer cells did not significantly 
increase tumor growth. However, we did find that, 
when adipose-derived stem cells and fat graft are 
co-injected with breast cancer cells (analogous to 
an enriched fat graft), tumor growth increased 
significantly.
Fig. 3. Graph showing the tumor growth rates in the study groups after 
subtraction of the volume of fat tissue. Group IV injected with breast can-
cer cells plus adipose-derived stem cells plus fat graft showed the high-
est rate of tumor growth. The difference between group IV and groups I 
and II was significant at almost all time points as marked by asterisks. The 
tumors in group III injected with breast cancer cells plus fat graft also grew 
faster than the tumors in groups I and II, but this difference did not achieve 
statistical significance. Injection of human adipose-derived stem cells with 
breast cancer cells (group II) did not affect the tumor growth rates com-
pared with breast cancer cells only (group I). *p < 0.05.
Copyright © 2018 American Society of Plastic Surgeons. Unauthorized reproduction of this article is prohibited. 
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DISCUSSION
Experimental Design
In this study, we aimed to inject equal doses of 
adipose-derived stem cells (1.8 × 105) into all the 
animals in study groups II and IV to standardize 
our experimental methods. However, because the 
fat grafts that we injected into animals in groups III 
and IV also contained adipose-derived stem cells, 
we have inevitably injected more human adipose-
derived stem cells into mice in these groups. In 
contrast, 1 ml of lipoaspirate yields an average of 
Fig. 5. (Left) Von Willebrand factor staining for vessel count. The nuclei are seen in blue, whereas the von Willebrand factor–positive 
vascular endothelium is seen in green. (Right) The average number of vessels per high-power field was highest in group IV. *p < 
0.05. Microbar = 100 μm.
Fig. 4. (Left) Representative hematoxylin and eosin–stained sections of the breast cancer xenografts from each group. 
The fat tissue injected in groups III and IV was largely replaced by breast cancer tissue, but there were still varying 
amounts of fat tissue within the tumors. Microbar = 500 μm. (Right) The largest amount of remaining fat tissue was in 
group IV in terms of percentage volume, but the difference between the groups was not significant.
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Fig. 6. There were no DiO-positive human adipose-derived stem cells within the xenografts after 2 weeks, suggesting that the 
injected human adipose-derived stem cells did not survive. Microbar = 1000 μm. DAPI, 4′,6-diamidino-2-phenylindole.
Fig. 7. Representative images of hematoxylin and eosin–stained sections from livers and lungs of mice in study groups. There was 
no visible micrometastasis in either of these organs. Microbar = 1000 μm. BrCa, breast cancer cells; ASCs, adipose-derived stem cells.
Copyright © 2018 American Society of Plastic Surgeons. Unauthorized reproduction of this article is prohibited. 
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3.75 × 105 cells, and we injected 0.075 ml of fat per 
injection site; therefore, there were approximately 
2.8 × 104 adipose-derived stem cells in the fat grafts, 
which is quite negligible compared to the number 
of adipose-derived stem cells injected in groups 
II and IV (1.8 × 105). We therefore hypothesized 
that it was the interactions between the fat grafts 
and adipose-derived stem cells that resulted in 
significantly higher breast cancer growth rates in 
the adipose-derived stem cell plus fat graft group, 
as opposed to the raw human adipose-derived 
stem cell numbers. In addition, if raw numbers of 
human adipose-derived stem cells were the main 
determining factor for tumor growth, we would 
expect group II to have grown larger tumors than 
group III, which we did not observe.
With respect to fat quantification within 
tumors, the reader will note that we did not use 
perilipin or any other specific immunologic stain-
ing to quantify the fat tissue within the tumors. 
Instead, we quantified the amount of fat tissue 
based on hematoxylin and eosin–stained slides. 
Our rationale for this method of quantification 
was to avoid the error introduced by background 
staining that is frequently encountered in immu-
nologic staining methods as we have also observed 
in our previous experiments. Even though it is a 
simpler staining method compared with immuno-
logic staining, we found hematoxylin and eosin 
staining to be more accurate in certain cases, 
given that a careful evaluation and observation is 
performed under the microscope.
Results
Late recurrence of breast cancer is usually attrib-
utable to dormant cancer cells.23 Much of the con-
troversy in the literature regarding the interaction 
of human adipose-derived stem cells with dormant 
breast cancer cells stems from opposing results of in 
vitro and in vivo/clinical studies as observed in our 
study. Human adipose-derived stem cells increased 
the in vitro migration of breast cancer cells, but 
injection of human adipose-derived stem cells 
with breast cancer cells to the mammary fat pads 
of mice did not increase the tumor growth rate. 
There might be several reasons for this discrepancy 
stemming from the in vitro and in vivo behavior of 
human adipose-derived stem cells. Several articles 
Fig. 8. Results of red fluorescent protein staining. The breast cancer cells stained positive for red fluorescent protein (below, right); 
however, there was no positivity in the lung or liver sections. Microbar = 500 μm. BrCa, breast cancer cells; ASCs, adipose-derived 
stem cells; Tx Red, Texas Red; Ab, antibody; RFP+, red fluorescent protein–positive.
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reported that injected mesenchymal stem cells do 
not survive in vivo because of the lack of an imme-
diate vascular supply after transplantation.24,25 The 
cell growth medium effectively delivers the nutri-
ents to the cells in the in vitro cultures, but the access 
of the cells to the nutrients in vivo relies solely on 
neovascularization after transplantation. A delay 
in neovascularization unquestionably leads to cell 
death and decreases the biological effectiveness 
of the injected cells. Therefore, adipose-derived 
stem cells in our study might not have survived 
long enough to exhibit their stimulatory biological 
effects on breast cancer cells, except in the breast 
cancer cell plus adipose-derived stem cell plus fat 
graft group, where the adipose-derived stem cells 
may have lasted longer because of trophic support 
from being in their native environment. In addi-
tion, breast cancer cells are fast-growing cells and 
potentially outcompeted the adipose-derived stem 
cells in terms of access to locally available nutrients 
and blood supply, thereby accelerating the death 
of adipose-derived stem cells in vivo. These hypoth-
eses were supported by the lack of DiO-positive 
adipose-derived stem cells in the histologic sections 
of breast cancer xenografts at the end of 2 weeks.
The complexity of the in vivo environment is 
another potential reason for the differential find-
ings between in vivo and in vitro studies. Even 
though adipose-derived stem cells increased the 
migration of breast cancer cells in vitro, the in 
vivo environment is much more complex, and 
several other cues come into play that may inter-
rupt the interaction between breast cancer cells 
and adipose-derived stem cells.23 Adipose-derived 
stem cells secrete multiple important growth fac-
tors, cytokines, chemokines, and inflammatory 
biomarkers linked to cancer development and 
progression.26 Adipose tissue is also a highly active 
endocrine organ and can influence distant tumor 
sites by means of endocrine function and soluble 
factors.27 These soluble factors, such as leptin and 
estrogen, facilitate interactions between stromal 
cells and tumor cells, creating a specific peri-
tumoral microenvironment (Fig. 1).27,28 When 
adipose-derived stem cells are transferred to a 
new location in their natural environment (i.e., 
mixed with fat grafts such as in group IV in this 
study), the preserved interaction between the fat 
tissue and adipose-derived stem cells may poten-
tiate the effects of both tissues, thereby explain-
ing the increased breast cancer xenograft growth 
rates that we observed in group IV (i.e., breast 
cancer cells plus adipose-derived stem cells plus 
fat graft). Another potential hypothesis could 
be that the absolute number of adipose-derived 
stem cells starting out in a sample is the main 
factor impacting tumor growth. However, we 
believe this to be relatively less likely, as we would 
expect the group with breast cancer and adipose-
derived stem cells to grow relatively more than 
the breast cancer cell plus fat graft group, which 
we did not see.
Another confounding factor in the literature 
is that the majority of the published experimental 
studies use immortalized cancer cell lines, which 
are aggressive and designed to give rise to large 
tumors in a very short time. This experimental 
model fails to approximate the crucial aspects 
of tumor heterogeneity, tumor dormancy, and 
reactivation of occult tumor cells.23 The experi-
mental models using immortalized breast can-
cer cells bear relevance only to rapidly growing, 
high-grade breast cancer tumors, where recon-
structive surgery likely would not be a consider-
ation.23 The importance of tumor heterogeneity 
was also emphasized by studies by Donnenberg 
et al.29,30 In these studies, despite the fact that all 
breast cancer cells were phenotypically the same 
(CD90+), human adipose-derived stem cells failed 
to augment the tumorigenicity of dormant breast 
cancer cells, whereas they markedly enhanced 
tumorigenesis mediated by the active cells. Based 
on this finding, the authors claimed that the tran-
sition between dormant and active states requires 
genetic reprogramming and not merely the pres-
ence of signals such as those provided by cytokines 
and growth factors secreted by adipose-derived 
stem cells. Therefore, they argued that the intro-
duction of adipose-derived stem cells to the site of 
a tumor bed would be noncontributory to local 
recurrence.
We did not observe any increase in the inter-
nal organ micrometastasis with the injection of fat 
grafts or enriched fat grafts. However, in our pilot 
study, we allowed the mice to survive for 3 weeks 
instead of 2 weeks and observed several internal 
organ metastases in the livers of mice. The num-
ber of liver micrometastases in group IV, injected 
with enriched fat grafts, was significantly higher 
compared with other groups. (See Figure, Supple-
mental Digital Content 2, which shows the micro-
metastases in the livers of the mice that survived 
for 3 weeks in our pilot study. Dashed circles point to 
the metastases. Microbar = 50 μm. The number of 
micrometastases was significantly higher in group 
IV compared with other groups. *p < 0.05. BrCa, 
breast cancer cells; hASCs, human adipose-derived 
stem cells, http://links.lww.com/PRS/D98.) It is a 
well-known fact that organ metastasis of malig-
nant tumors is a time-dependent event. The more 
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advanced the tumor, the higher the risk of inter-
nal organ metastasis; this may explain the lack of 
internal organ metastases at the 2-week mark in 
our study. We allowed the animals to survive for 
just 2 weeks in the current study because the tumor 
burden that we observed in the pilot study was con-
cerning from an ethical standpoint. Based on these 
results, we hypothesize that enriched fat grafting 
increases not only breast cancer growth but also 
internal organ metastases in a time-dependent 
fashion. Importantly, this hypothesis is relatively 
weakened by the limitations of our model. Despite 
our best efforts, animal models are not perfect 
representations of human disease. In our in vivo 
study, we chose an immunocompromised model to 
avoid rejection of human fat grafts. Inoculation of 
a highly aggressive human breast cancer cell line in 
an immunocompromised murine model may not 
accurately reflect the complex tumor-host interac-
tions in the majority of breast cancer patients.
The existing clinical data convincingly doc-
umented the lack of increased breast cancer 
recurrence rates after postmastectomy fat graft-
ing.31 Petit et al. in 2011 published a multicenter 
analysis of 513 patients who underwent fat graft-
ing and reported that the local and distant recur-
rence rates were comparable with the patients 
who did not undergo postmastectomy fat grat-
ing.17 The same group analyzed 321 consecutive 
patients against a 1:2 matched cohort with similar 
characteristics and found no difference in recur-
rence rates.16 However, when analysis was limited 
to a subset of 37 patients with intraepithelial neo-
plasms, the local recurrence rate increased signifi-
cantly to 10.8 percent versus none in the cohort 
control.16 The initial findings prompted the team 
to perform a matched cohort study of 59 patients 
with intraepithelial neoplasms compared to 118 
matched control patients with intraepithelial neo-
plasms who did not receive fat grafts. This study 
revealed an 18 percent 5-year cumulative risk of 
local recurrence in the breast fat grafting group 
compared to 3 percent in the control cohort (p 
= 0.02).18 Intraepithelial neoplasms being an 
exception, following clinical articles again failed 
to detect any increase in breast cancer recurrence 
rates after postmastectomy fat grafting.32,33 In a 
previously published literature review, we com-
piled 16 clinical studies including 2100 patients 
and found that the overall rate of local breast can-
cer recurrence after fat grafting was 2.2 percent.34 
These results were again comparable to the fig-
ures reported in patients who did not undergo 
postmastectomy fat grafting.35,36 Our in vivo 
results parallel results of clinical studies, with both 
demonstrating that nonenriched fat grafts do not 
appear to increase tumor growth in the oncologic 
patient. Thus, our data help clarify the ongoing 
discrepancy between the basic scientific and clini-
cal studies showing that fat graft alone does not 
appear to impact tumor growth.
Fat grafting is a useful tool for breast recon-
struction and augmentation, and adipose-derived 
stem cells increase the viability of injected fat 
grafts.37,38 However, it is important to note that 
the use of enriched fat grafting in our model did 
significantly increase breast cancer growth, sug-
gesting that enriched autologous fat grafting in 
the oncologic patient could potentially increase 
recurrence rates and growth of any residual 
breast cancer cells. Therefore, despite the tempta-
tion because of improved fat graft retention, we 
strongly recommend caution and close surveil-
lance when using enriched fat grafting for onco-
logic breast reconstruction until more robust 
clinical safety data are available. In addition, we 
have changed our aesthetic practice such that we 
do not offer enriched fat grafting to augmenta-
tion patients with a family history of breast cancer 
genes such as BRCA1 and BRCA2.
CONCLUSIONS
Fat grafting alone does not increase the growth 
of breast cancer xenografts significantly. Com-
bined with the clinical data in the literature, our 
results demonstrate the safety of fat grafting for 
postmastectomy and oncologic breast reconstruc-
tion. However, co-injection of fat grafts enriched 
with adipose-derived stem cells should be used 
with caution, at least until cancer remission can 
be firmly established and higher level clinical data 
are available.
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Division of Plastic Surgery
University of California, Davis Medical Center
4625 2nd Avenue, Room 3001
Sacramento, Calif. 95817
horbay@ucdavis.edu
REFERENCES
 1. Spear SL, Coles CN, Leung BK, Gitlin M, Parekh M, Macarios 
D. The safety, effectiveness, and efficiency of autologous 
fat grafting in breast surgery. Plast Reconstr Surg Glob Open 
2016;4:e827.
 2. Report on autologous fat transplantation. ASPRS Ad-Hoc 
Committee on New Procedures, September 30, 1987. Plast 
Surg Nurs. 1987;7:140–141.
 3. Coleman SR. Hand rejuvenation with structural fat graft-
ing. Plast Reconstr Surg. 2002;110:1731–1744; discussion 
1745–1747.
Copyright © 2018 American Society of Plastic Surgeons. Unauthorized reproduction of this article is prohibited. 
Volume 142, Number 6 • Breast Cancer and Fat Grafting
1499
 4. American Society of Plastic Surgeons. 2012 plastic surgery 
statistics. Available at: http://www.plasticsurgery.org/news-
and-resources/2012-plastic-surgery-statistics.html. Accessed 
October 8, 2013.
 5. Gutowski KA; ASPS Fat Graft Task Force. Current applica-
tions and safety of autologous fat grafts: A report of the ASPS 
Fat Graft Task Force. Plast Reconstr Surg. 2009;124:272–280.
 6. Coleman SR. Structural fat grafts: The ideal filler? Clin Plast 
Surg. 2001;28:111–119.
 7. Khouri R, Del Vecchio D. Breast reconstruction and aug-
mentation using pre-expansion and autologous fat trans-
plantation. Clin Plast Surg. 2009;36:269–280, viii.
 8. Kølle SF, Fischer-Nielsen A, Mathiasen AB, et al. Enrichment 
of autologous fat grafts with ex-vivo expanded adipose tissue-
derived stem cells for graft survival: A randomised placebo-
controlled trial. Lancet 2013;382:1113–1120.
 9. Zuk PA, Zhu M, Mizuno H, et al. Multilineage cells from 
human adipose tissue: Implications for cell-based therapies. 
Tissue Eng. 2001;7:211–228.
 10. Bertolini F, Petit JY, Kolonin MG. Stem cells from adipose 
tissue and breast cancer: Hype, risks and hope. Br J Cancer 
2015;112:419–423.
 11. Schweizer R, Tsuji W, Gorantla VS, Marra KG, Rubin JP, Plock 
JA. The role of adipose-derived stem cells in breast cancer 
progression and metastasis. Stem Cells Int. 2015;2015:120949.
 12. Park J, Euhus DM, Scherer PE. Paracrine and endocrine 
effects of adipose tissue on cancer development and progres-
sion. Endocr Rev. 2011;32:550–570.
 13. van Kruijsdijk RC, van der Wall E, Visseren FL. Obesity and 
cancer: The role of dysfunctional adipose tissue. Cancer 
Epidemiol Biomarkers Prev. 2009;18:2569–2578.
 14. Charvet HJ, Orbay H, Harrison L, Devi K, Sahar DE. In 
vitro effects of adipose-derived stem cells on breast can-
cer cells harvested from the same patient. Ann Plast Surg. 
2016;76(Suppl 3):S241–S245.
 15. Chandler EM, Seo BR, Califano JP, et al. Implanted adipose 
progenitor cells as physicochemical regulators of breast can-
cer. Proc Natl Acad Sci USA 2012;109:9786–9791.
 16. Petit JY, Botteri E, Lohsiriwat V, et al. Locoregional recur-
rence risk after lipofilling in breast cancer patients. Ann 
Oncol. 2012;23:582–588.
 17. Petit JY, Lohsiriwat V, Clough KB, et al. The oncologic out-
come and immediate surgical complications of lipofilling in 
breast cancer patients: A multicenter study. Milan-Paris-Lyon 
experience of 646 lipofilling procedures. Plast Reconstr Surg. 
2011;128:341–346.
 18. Petit JY, Rietjens M, Botteri E, et al. Evaluation of fat grafting 
safety in patients with intraepithelial neoplasia: A matched-
cohort study. Ann Oncol. 2013;24:1479–1484.
 19. Chaput B, Grolleau JL, Bertheuil N, Eburdery H, Chavoin 
JP, Garrido I. Another suspected case of breast cancer recur-
rence after lipofilling? Remain cautious …. J Plast Reconstr 
Aesthet Surg. 2014;67:1156–1157.
 20. Smit JM, Tielemans HJ, de Vries B, Tuinder SM. Recurrence of 
invasive ductal breast carcinoma 10 months after autologous 
fat grafting. J Plast Reconstr Aesthet Surg. 2014;67:e127–e128.
 21. Orbay H, Devi K, Williams PA, Dehghani T, Silva EA, Sahar 
DE. Comparison of endothelial differentiation capacities of 
human and rat adipose-derived stem cells. Plast Reconstr Surg. 
2016;138:1231–1241.
 22. Schneider CA, Rasband WS, Eliceiri KW. NIH Image 
to ImageJ: 25 years of image analysis. Nat Methods 
2012;9:671–675.
 23. Donnenberg VS, Zimmerlin L, Rubin JP, Donnenberg AD. 
Regenerative therapy after cancer: What are the risks? Tissue 
Eng Part B Rev. 2010;16:567–575.
 24. Jain RK, Au P, Tam J, Duda DG, Fukumura D. Engineering 
vascularized tissue. Nat Biotechnol. 2005;23:821–823.
 25. Rajan A, Eubanks E, Edwards S, et al. Optimized cell survival and 
seeding efficiency for craniofacial tissue engineering using clin-
ical stem cell therapy. Stem Cells Transl Med. 2014;3:1495–1503.
 26. Schäffler A, Schölmerich J, Buechler C. Mechanisms of dis-
ease: Adipokines and breast cancer. Endocrine and para-
crine mechanisms that connect adiposity and breast cancer. 
Nat Clin Pract Endocrinol Metab. 2007;3:345–354.
 27. Freese KE, Kokai L, Edwards RP, et al. Adipose-derived stems 
cells and their role in human cancer development, growth, 
progression, and metastasis: A systematic review. Cancer Res. 
2015;75:1161–1168.
 28. Key TJ, Appleby PN, Reeves GK, et al.; Endogenous 
Hormones Breast Cancer Collaborative Group. Body mass 
index, serum sex hormones, and breast cancer risk in post-
menopausal women. J Natl Cancer Inst. 2003;95:1218–1226.
 29. Donnenberg VS, Donnenberg AD, Zimmerlin L, et al. 
Localization of CD44 and CD90 positive cells to the invasive 
front of breast tumors. Cytometry B Clin Cytom. 2010;78:287–301.
 30. Donnenberg VS, Luketich JD, Landreneau RJ, DeLoia JA, 
Basse P, Donnenberg AD. Tumorigenic epithelial stem cells 
and their normal counterparts. Ernst Schering Found Symp 
Proc. 2006;5:245–263.
 31. Delay E, Garson S, Tousson G, Sinna R. Fat injection to the 
breast: Technique, results, and indications based on 880 pro-
cedures over 10 years. Aesthet Surg J. 2009;29:360–376.
 32. Gale KL, Rakha EA, Ball G, Tan VK, McCulley SJ, Macmillan 
RD. A case-controlled study of the oncologic safety of fat 
grafting. Plast Reconstr Surg. 2015;135:1263–1275.
 33. Pérez-Cano R, Vranckx JJ, Lasso JM, et al. Prospective trial of 
adipose-derived regenerative cell (ADRC)-enriched fat graft-
ing for partial mastectomy defects: The RESTORE-2 trial. 
Eur J Surg Oncol. 2012;38:382–389.
 34. Charvet HJ, Orbay H, Wong MS, Sahar DE. The oncologic 
safety of breast fat grafting and contradictions between basic 
science and clinical studies: A systematic review of the recent 
literature. Ann Plast Surg. 2015;75:471–479.
 35. Veronesi U, Cascinelli N, Mariani L, et al. Twenty-year follow-
up of a randomized study comparing breast-conserving sur-
gery with radical mastectomy for early breast cancer. N Engl J 
Med. 2002;347:1227–1232.
 36. Fisher B, Anderson S, Bryant J, et al. Twenty-year follow-up 
of a randomized trial comparing total mastectomy, lumpec-
tomy, and lumpectomy plus irradiation for the treatment of 
invasive breast cancer. N Engl J Med. 2002;347:1233–1241.
 37. Yoshimura K, Sato K, Aoi N, Kurita M, Hirohi T, Harii K. 
Cell-assisted lipotransfer for cosmetic breast augmenta-
tion: Supportive use of adipose-derived stem/stromal cells. 
Aesthetic Plast Surg. 2008;32:48–55; discussion 56–57.
 38. Matsumoto D, Sato K, Gonda K, et al. Cell-assisted lipo-
transfer: Supportive use of human adipose-derived cells 
for soft tissue augmentation with lipoinjection. Tissue Eng. 
2006;12:3375–3382.
